185 related articles for article (PubMed ID: 8977510)
1. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity.
Ciprandi G; Pronzato C; Passalacqua G; Ricca V; Grögen J; Mela GS; Varese P; Bertolini C; Bagnasco M; Canonica GW
J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1088-96. PubMed ID: 8977510
[TBL] [Abstract][Full Text] [Related]
2. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge.
Ciprandi G; Tosca MA; Passalacqua G; Canonica GW
Ann Allergy Asthma Immunol; 2001 Apr; 86(4):433-8. PubMed ID: 11345288
[TBL] [Abstract][Full Text] [Related]
3. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy.
Ciprandi G; Pronzato C; Ricca V; Varese P; Del Giacco GS; Canonica GW
Clin Exp Allergy; 1995 Sep; 25(9):871-8. PubMed ID: 8564726
[TBL] [Abstract][Full Text] [Related]
4. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression.
Ciprandi G; Pronzato C; Ricca V; Passalacqua G; Danzig M; Canonica GW
Clin Exp Allergy; 1997 Oct; 27(10):1175-83. PubMed ID: 9383258
[TBL] [Abstract][Full Text] [Related]
5. Seasonal rhinitis and azelastine: long- or short-term treatment?
Ciprandi G; Ricca V; Passalacqua G; Truffelli T; Bertolini C; Fiorino N; Riccio AM; Bagnasco M; Canonica GW
J Allergy Clin Immunol; 1997 Mar; 99(3):301-7. PubMed ID: 9058684
[TBL] [Abstract][Full Text] [Related]
6. Effects of intranasal azelastine on the response to nasal allergen challenge.
Saengpanich S; Assanasen P; deTineo M; Haney L; Naclerio RM; Baroody FM
Laryngoscope; 2002 Jan; 112(1):47-52. PubMed ID: 11802037
[TBL] [Abstract][Full Text] [Related]
7. Intranasal fluticasone propionate reduces ICAM-1 on nasal epithelial cells both during early and late phase after allergen challenge.
Ciprandi G; Ricca V; Passalacqua G; Fasolo A; Canonica GW
Clin Exp Allergy; 1998 Mar; 28(3):293-9. PubMed ID: 9543078
[TBL] [Abstract][Full Text] [Related]
8. Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions.
Ciprandi G; Cosentino C; Milanese M; Tosca MA
Ann Allergy Asthma Immunol; 2003 Apr; 90(4):434-8. PubMed ID: 12722967
[TBL] [Abstract][Full Text] [Related]
9. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
Ciprandi G; Buscaglia S; Catrullo A; Pesce G; Fiorino N; Montagna P; Bagnasco M; Canonica GW
Clin Exp Allergy; 1997 Feb; 27(2):182-91. PubMed ID: 9061218
[TBL] [Abstract][Full Text] [Related]
10. Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation.
Passalacqua G; Albano M; Ruffoni S; Pronzato C; Riccio AM; Di Berardino L; Scordamaglia A; Canonica GW
Am J Respir Crit Care Med; 1995 Aug; 152(2):461-6. PubMed ID: 7633693
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluticasone propionate aqueous nasal spray on allergen-induced inflammatory changes in the nasal airways of allergic rhinitics following exposure to nitrogen dioxide.
Wang JH; Devalia JL; Rusznak C; Bagnall A; Sapsford RJ; Davies RJ
Clin Exp Allergy; 1999 Feb; 29(2):234-40. PubMed ID: 10051728
[TBL] [Abstract][Full Text] [Related]
12. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity.
Ciprandi G; Tosca M; Ricca V; Passalacqua G; Riccio AM; Bagnasco M; Canonica GW
Clin Exp Allergy; 1997 Oct; 27(10):1160-6. PubMed ID: 9383256
[TBL] [Abstract][Full Text] [Related]
13. Cytokines and eosinophil-derived cationic proteins upregulate intercellular adhesion molecule-1 on human nasal epithelial cells.
Altman LC; Ayars GH; Baker C; Luchtel DL
J Allergy Clin Immunol; 1993 Oct; 92(4):527-36. PubMed ID: 8104967
[TBL] [Abstract][Full Text] [Related]
14. Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma.
Fasce L; Ciprandi G; Pronzato C; Cozzani S; Tosca MA; Grimaldi I; Canonica GW
Int Arch Allergy Immunol; 1996 Mar; 109(3):272-6. PubMed ID: 8620097
[TBL] [Abstract][Full Text] [Related]
15. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro.
Buscaglia S; Paolieri F; Catrullo A; Fiorino N; Riccio AM; Pesce G; Montagna P; Bagnasco M; Ciprandi G; Canonica GW
Clin Exp Allergy; 1996 Oct; 26(10):1188-96. PubMed ID: 8911706
[TBL] [Abstract][Full Text] [Related]
16. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season.
Wang D; Smitz J; De Waele M; Clement P
Int Arch Allergy Immunol; 1997 Oct; 114(2):185-92. PubMed ID: 9338613
[TBL] [Abstract][Full Text] [Related]
17. Azelastine reduces mediators of inflammation in patients with nasal polyps.
Mösges R; Klimek L
Allergy Asthma Proc; 1998; 19(6):379-83. PubMed ID: 9876778
[TBL] [Abstract][Full Text] [Related]
18. Eosinophils and eosinophil cationic protein in nasal lavages in allergen-induced hyperresponsiveness: effects of topical glucocorticosteroid treatment.
Andersson M; Andersson P; Venge P; Pipkorn U
Allergy; 1989 Jul; 44(5):342-8. PubMed ID: 2669553
[TBL] [Abstract][Full Text] [Related]
19. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine.
Jacobi HH; Skov PS; Poulsen LK; Malling HJ; Mygind N
J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):768-72. PubMed ID: 10329808
[TBL] [Abstract][Full Text] [Related]
20. Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects. Relationships with early and late inflammatory phenomena.
Ciprandi G; Pronzato C; Ricca V; Passalacqua G; Bagnasco M; Canonica GW
Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1653-9. PubMed ID: 7524984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
